Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer
30 mai 2024 03h00 HE
|
Curium
first doses of PYLCLARI in France for prostate cancer patients
Curium annonce les premieres doses commerciales en France de PYLCLARI® - un traceur PET innovant 18F-PSMA indique dans le cancer de la prostate
30 mai 2024 03h00 HE
|
Curium US LLC
PARIS, 30 mai 2024 (GLOBE NEWSWIRE) -- Curium, leader mondial de la médecine nucléaire, annonce aujourd'hui que suite à la Publication au Journal Officiel du 2 mai, , les patients français ont reçu...
Curium Extends Irradiation Partnership With NRG I PALLAS in Netherlands for Continuous Supply of Lutetium-177 to Treat 1,000s of Cancer Patients Each Year
29 mai 2024 03h32 HE
|
Curium
PARIS, May 29, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that it has signed a long-term agreement to extend its current partnership with NRG I PALLAS for...
Curium: Erste Kommerzielle Dosen von PYLCLARI® in Deutschland Verfügbar - Ein Innovativer 18f-PSMA PET Tracer für Patienten Mit Prostatakrebs
06 mai 2024 04h25 HE
|
Curium
PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, ein weltweit führendes Unternehmen der Nuklearmedizin, gab heute bekannt, dass in München und Nürnberg die ersten kommerziellen Dosen von PYLCLARI®...
Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
06 mai 2024 04h25 HE
|
Curium
Curium announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered.
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
23 avr. 2024 00h01 HE
|
Curium
patient enrollment in clinical trial
Curium Announces First Commercial Dose in the Netherlands of PYLCLARI® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
09 avr. 2024 08h50 HE
|
Curium
Curium proudly introduces the first commercial dose of PYLCLARI® in the Netherlands, revolutionizing prostate cancer diagnosis. This innovative 18F-PSMA PE
핵의학 기업 Curium, Eczacibaşi-Monrol 인수 통해 Lutetium-177 생산능력 강화와 PET 입지 확대 전망
09 avr. 2024 04h13 HE
|
Curium US LLC
Eczacıbaşı-Monrol 인수 제안에 대한 내용은 다음과 같다: 이미 진행되고 있는 기존의 Lu-177 파트너십에 기반해 동위원소 제조분야의 선도적인 기업을 구축한다.현재 Curium이 진출하지 않은 지역을 대상으로 12개의 PET 사이트를 Curum의 기존 네트워크에 포함시킨다.Curium은 SPECT 제조 역량과 광범위한 물류 인프라를 추가로...
Curium 计划通过收购 Eczacibaşi-Monrol 的协议大幅扩大镥-177 产能及 PET 业务范围
09 avr. 2024 04h13 HE
|
Curium US LLC
此项拟议的 Eczacıbaşı-Monrol 收购将： 在现有的镥-177 合作伙伴关系基础上，创立领先的同位素制造商在 Curium 目前没有业务的地区为其现有网络增加 12 个 PET 站点为 Curium 增加 SPECT 生产能力和广泛的物流基础设施提高诊断和治疗方案的可靠性，从而造福患者 巴黎, April 09, 2024 (GLOBE NEWSWIRE) --...
Curium plant mit der Vereinbarung zur Übernahme von Eczacıbaşı-Monrol eine erhebliche Ausweitung der Lutetium-177-Kapazitäten und der Präsenz im PET-Bereich
09 avr. 2024 04h13 HE
|
Curium
Die geplante Übernahme von Eczacıbaşı-Monrol soll Folgendes erreichen: Ausbau der bestehenden Partnerschaft im Bereich Lu-177, um führender Hersteller des Isotops zu werdenErweiterung des bestehenden...